drugset / Trial / NCT01744912
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether ublituximab in combination with lenalidomide (Revlimid®) is safe and effective in patients with B-Cell Lymphoid Malignancies who have relapsed or are refractory after CD20 directed antibody therapy.
Timeline
- Start
- 2012-11-21
- Primary completion
- 2014-02-07
- Completion
- 2014-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Ublituximab | Monoclonal antibody | 450 mg | Intravenous |
| Subject | Ublituximab | Monoclonal antibody | 600 mg | Intravenous |
| Subject | Ublituximab | Monoclonal antibody | 900 mg | Intravenous |